CLDX
Celldex Therapeutics, Inc.
$33.97
+1.95%
2026-05-08
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Key Fundamentals
Forward P/E
-7.05
EPS (TTM)
$-3.90
ROE
-40.6%
Revenue Growth (YoY)
-89.7%
Profit Margin
0.0%
Debt/Equity
0.44
Price/Book
4.27
Beta
0.98
Market Cap
$2.66B
Avg Volume (10D)
651K
Recent Breakout Signals
No recent breakout signals detected for CLDX.
Recent Price Range (60 Days)
60D High
$35.79
60D Low
$22.46
Avg Volume
980K
Latest Close
$33.97
Get breakout alerts for CLDX
Sign up for Breakout Scanner to receive daily notifications when CLDX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Celldex Therapeutics, Inc. (CLDX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CLDX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CLDX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.